Patient description: The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed: IPSS score : 15 Post-void residual: 70 mL Prostate volume (TRUS): 60 mL Prostate-specific antigen (PSA) level: 3.2 ng/mL 10 mL/sec of maximum flow rate when urine volume was 130 mL He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: Hgb: 13.5 g/dl WBC: 135000 /mm3 Plt: 350000 /ml PT: 11 second PTT: 35 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Benign Prostate Hyperplasia Subject signed informed consent form (ICF) 2. Age 50 and above 3. Male with symptomatic BPH. 4. IPSS symptom severity score ≥ 10 5. Peak urinary flow of < 12 ml/sec . Meeting the criterion on (2) two separate voiding trials , on a minimum voided volume of at least 125 cc for each voiding trial. 6. Prostate volume between 25 ml to 75 ml (assessed by ultrasound) 7. Blood CBC and biochemistry up to two weeks before screening demonstrating: Normal values of the PT, PTT and INR tests (anticoagulants should be stopped according to GCP) 8. Subject able to comply with the study protocol 9. Normal Urinalysis and urine culture  Cardiac arrhythmias, cardiac disease including congestive heart failure, uncontrolled diabetes mellitus, significant respiratory disease, or known immunosuppression; 11. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes 12. A post void residual (PVR) volume > 250 ml measured by ultrasound or acute urinary retention 13. Compromised renal function (i.e., serum creatinine level > 1.8 mg/dl, or upper tract disease); 14. Confirmed or suspected bladder cancer; 15. Recent (within 3 months) cystolithiasis or hematuria; 16. Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology; 17. An active urinary tract infection. 18. Enrolled in another treatment trial for any disease within the past 30 days. 19. Previous colo rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used; 20. Previous pelvic irradiation, cryosurgery or radical pelvic surgery; 21. Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate 22. History of prostatitis within the past 5 years. 23. Median lobe obstruction of the prostate. 24. Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years). 25. Any serious medical condition likely to impede successful completion of the study 26. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study. 27. Subjects who are actively taking medications that affects urination and BPH symptoms not completing the required washout period. 28. Baseline PSA ≥ 10 ng/ml. 29. Positive DRE. 30. Baseline PSA between 2.5-10 ng/ml and free PSA < 25%, without a subsequent negative prostate biopsy